Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (NCT02008656)

🧪 Interventions in This Study

• Oxaliplatin (OXAL) (DRUG)
• 5-Fluorouracil (5-FU) (DRUG)
• Leucovorin (DRUG)
• Capecitabine (Xeloda®) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• University of California, Irvine — Irvine, California
• St. Joseph Hospital — Orange, California
• University of California San Francisco — San Francisco, California
• John Muir Health — Walnut Creek, California
• University of Colorado — Aurora, Colorado
• Washington Hospital Center — Washington D.C., District of Columbia
• University Of South Florida — Tampa, Florida
• Cleveland Clinic Florida — Weston, Florida
• University of Chicago — Chicago, Illinois
• University of Michigan — Northville, Michigan
• Washington University School of Medicine — St Louis, Missouri
• CHI Heath Bergan Mercy — Omaha, Nebraska
• Colon and Rectal Surgery, Incorporated — Omaha, Nebraska
• Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
• Memorial Sloan Kettering Bergen — Montvale, New Jersey
• Memorial Sloan Kettering Commack — Commack, New York
• Memorial Sloan Kettering Westchester — Harrison, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• University of Rochester Medical Center — Rochester, New York
• Memorial Sloan Kettering Cancer Center at Phelps — Sleepy Hollow, New York
• Memorial Sloan Kettering Nassau — Uniondale, New York
• Cleveland Clinic — Cleveland, Ohio
• Oregon Health & Science University — Portland, Oregon
• University of Vermont Medical Center — Burlington, Vermont
• University of Virginia — Charlottesville, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Rectal Cancer

• High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) — Tampa, Florida
• Microbiome and Rectal Cancer — Tampa, Florida
• Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence — Cleveland, Ohio
• Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial — St Louis, Missouri
• Multicenter Phase II Study of Transanal TME (taTME) — Los Angeles, California

Explore by condition: All Rectal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.